Latest News | Natco Pharma's Canadian Unit Signs Pact with Celgene for Cancer Treatment Drug
Get latest articles and stories on Latest News at LatestLY. Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
New Delhi, Jul 10 (PTI) Natco Pharma on Friday said its Canadian subsidiary has entered into a settlement agreement with biopharmaceutical firm Celgene (part of Bristol-Myers Squibb) for Lenalidomide capsules.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells.
Also Read | Apple iOS 14 & iPadOS 14 Beta Version Released, How to Download iOS 14 & iPadOS 14 Beta Update.
"Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Ltd has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada," the company said in a regulatory filing.
The terms of the agreement are confidential as per the agreement, the company added.
Also Read | Mi Notebook 14 & Mi Notebook 14 Horizon Edition to Go on Sale Today at 12 Noon via Amazon.in & Mi.com.
Shares of Natco Pharma were trading 0.15 per cent lower at Rs 676.50 apiece on BSE.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)